Clinical Trials Logo
  1. Home
  2. RRMM
  3. NCT04412707

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients — PORT  

RRMM Clinical Trial

Official title:
A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients

Clinical Trial Summary

This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM. It is an international study, enrolling patients in US and Europe. The study will enroll patients following at least 2 lines of prior therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04412707
Study type Interventional
Source Oncopeptides AB
Contact
Status Terminated
Phase Phase 2
Start date August 4, 2020
Completion date January 10, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03778346 - Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells Phase 1
Terminated NCT02684617 - Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) Phase 1